Public procurement of biologics should foster fair market competition says white paper

29 June 2015

Trade body EuropaBio, the European Association for Bioindustries, has launched a White Paper on the Public Procurement of Biological Medicines analyzing national practices for publicly procuring complex medicines, such as biologics, in Europe.

The paper presents the findings of a survey of EuropaBio member companies about national public procurement practices for biological medicines in the European Economic Area (EEA). It provides key recommendations to decision-makers on how to develop tenders to foster fair market competition and innovation for industry, while at the same time guaranteeing a high level of care for patients.

The recommendations were:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK